Dr. Nielsen on the Pros and Cons of the Ki67 Assay

Torsten O. Nielsen, MD, PhD, FRCPC
Published Online: Thursday, Sep 26, 2013

Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the pros and cons of using the Ki67 as a prognostic marker in breast cancer.

Nielsen says there is extensive literature on the clinical validity of Ki67. It is a marker of proliferation that assists in the prognosis of breast cancer and many believe an assay could have a role in the prediction of the disease. Nielsen also notes that testing for Ki67 could be a substitute for a more complex, expensive test.

However, the Ki-67 tumor marker test is not without problems, Nielsen says. There is poor analytical reproducibility with Ki67 scores, especially within the critical 10-20% range.

Although the fundamentals of the assay work well, Nielsen says, the scoring and interpretation of the test are difficult to reproduce.

Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the pros and cons of using the Ki67 as a prognostic marker in breast cancer.

Nielsen says there is extensive literature on the clinical validity of Ki67. It is a marker of proliferation that assists in the prognosis of breast cancer and many believe an assay could have a role in the prediction of the disease. Nielsen also notes that testing for Ki67 could be a substitute for a more complex, expensive test.

However, the Ki-67 tumor marker test is not without problems, Nielsen says. There is poor analytical reproducibility with Ki67 scores, especially within the critical 10-20% range.

Although the fundamentals of the assay work well, Nielsen says, the scoring and interpretation of the test are difficult to reproduce.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 33rd Annual Miami Breast Cancer Conference®May 18, 20172.0
Medical Crossfire®: Integrating CDK4/6 Inhibitors into the Management of Breast CancersMay 26, 20171.5
Publication Bottom Border
Border Publication